Ascendis Pharma A/S (ASND) — Financial statements
Income statement, balance sheet, and cash flow for Ascendis Pharma A/S — annual and quarterly history with growth and margin analysis.
| Metric (EUR Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 692↑90.2% | 364↑36.3% | 267↑421.2% | 51↑557.9% | 8 | |
| Cost of Revenue | 103↑133.1% | 44↓0.3% | 44↑265.8% | 12↑244.5% | 4 | |
| Gross Profit | 589↑84.3% | 319↑43.7% | 222↑469.5% | 39↑817.4% | 4 | |
| Operating Expenses | ||||||
| R&D Expenses | 284↓7.7% | 307↓25.7% | 413↑8.9% | 380↑28.3% | 296 | |
| General & Administrative Expenses | 0.00↓100.0% | 285↑10.0% | 259↑19.9% | 216 | 0.00 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 436↑53.2% | 285↑10.0% | 259↑19.9% | 216↑34.8% | 160 | |
| Other Expenses | 0.00↓100.0% | 7↑17.3% | 6↑4.6% | 5 | 0.00 | |
| Operating Expenses | 719↑20.3% | 598↓11.8% | 678↑12.8% | 601↑31.8% | 456 | |
| Total Costs & Expenses | 823↑28.1% | 642↓11.1% | 722↑17.8% | 613↑33.4% | 460 | |
| Operating Results | ||||||
| Operating Income | -131↑53.0% | -279↑38.8% | -456↑18.9% | -562↓24.4% | -452 | |
| Depreciation & Amortization | 17↓4.0% | 18↓6.3% | 19↑8.0% | 18↑13.8% | 15 | |
| EBITDA | -114↑60.7% | -290↑29.5% | -411↑22.3% | -529↓45.1% | -365 | |
| EBIT | -131↑57.5% | -308↑28.4% | -430↑21.4% | -547↓44.0% | -380 | |
| Interest & Other Income | ||||||
| Net Interest Income | -63↓22.7% | -51↓88.0% | -27↓17.0% | -23↓622.5% | -3 | |
| Interest Income | 15↑2.3% | 14↓14.8% | 17↑127.0% | 7↑973.1% | 0.69 | |
| Interest Expense | 77↑18.3% | 66↑48.7% | 44↑43.6% | 31↑684.5% | 4 | |
| Non-Operating Income | 0.00↓100.0% | 29↑213.8% | -25↓73.5% | -15↑79.5% | -72 | |
| Other Income / Expenses | -73↑22.3% | -94↓407.9% | -19↓16.2% | -16↓123.6% | 68 | |
| Income Before Tax | -204↑45.3% | -373↑21.3% | -474↑17.9% | -578↓50.5% | -384 | |
| Income Tax Expense | 15↑205.1% | 5↓33.7% | 7↑35.8% | 5↑1565.1% | -0.37 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -219↑42.1% | -378↑21.5% | -481↑17.4% | -583↓52.0% | -384 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -219↑42.1% | -378↑21.5% | -481↑17.4% | -583↓52.0% | -384 | |
| Bottom-Line Net Income | -219↑42.1% | -378↑21.5% | -481↑17.4% | -583↓52.0% | -384 | |
| EPS (Basic) | -3.62↑44.6% | -6.53↑23.6% | -8.55↑17.8% | -10.40↓48.6% | -7.00 | |
| EPS (Diluted) | -3.62↑44.6% | -6.53↑23.6% | -8.55↑17.8% | -10.40↓48.6% | -7.00 | |
| Weighted Average Shares | 61↑4.7% | 58↑2.9% | 56↑0.4% | 56↑2.4% | 55 | |
| Weighted Average Diluted Shares | 61↑4.7% | 58↑2.9% | 56↑0.4% | 56↑2.4% | 55 | |
* All figures in Millions of EUR, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.